Mashup Score:5
OncLiveDr. Heymach on the Potential Utility of Afatinib in NRG1 Fusion+ NSCLC - 2 days
Mashup Score:5
Twitter Feed: OncLive.com
Mashup Score:4
OncLiveFDA Approves Nivolumab for Frontline Gastric Cancer - 1 day
Mashup Score:4
The FDA has approved nivolumab to be combined with select types of chemotherapy for the frontline treatment of patients with advanced or metastatic gastric...
-
BREAKING: @US_FDA Approves Nivolumab for Frontline Gastric Cancer #gicsm https://t.co/rhEHKgmlK5 https://t.co/rhEHKgmlK5 - view on twitter
More coverage:
#gicsm
Mashup Score:4
OncLiveNivolumab/Ipilimumab Showcases Significant Antitumor Activity in Metastatic CRPC - 2 days
Mashup Score:4
Nivolumab plus ipilimumab was found to induce significant antitumor activity when administered to patients with metastatic castration-resistant prostate cancer and immunogenic...
-
Nivolumab plus ipilimumab was found to induce significant antitumor activity when administered to patients with metastatic castration-resistant prostate cancer and immunogenic signature. @AACR #AACR21 #pcsm https://t.co/0ZkctNJpws - view on twitter
Mashup Score:3
OncLivePal Previews Potential Avenues to Produce More Second-Line Options and Beyond in RCC - 2 days
Mashup Score:3
Sumanta K. Pal, MD, details ongoing research efforts dedicated to providing additional therapeutic options for patients with renal cell carcinoma in the second-line setting...
-
Pal Previews Potential Avenues to Produce More Second-Line Options and Beyond in RCC @montypal @cityofhope #kcsm https://t.co/uNFAMqtjt9 - view on twitter
More coverage:
#kcsm
Mashup Score:2
OncLiveNivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite...
-
Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, MSI–H/MMRD or PD-L1+ advanced gastric cancer. @AACR #AACR21 #gicsm https://t.co/BuTJcdwK7I - view on twitter
Mashup Score:2
OncLiveDr. Kröger on the Role of Allogenic Stem Cell Transplant in Multiple Myeloma - 2 days
Mashup Score:2
Nicolaus Kröger, MD, discusses the role of allogenic stem cell transplant in patients with multiple...
-
Nicolaus Kröger, MD, of @Eppendorf_AG discusses the role of allogenic stem cell transplant in patients with multiple myeloma. #mmsm https://t.co/hmOAqLWiVF - view on twitter
More coverage:
#mmsm
Mashup Score:2
OncLiveAdjuvant Nivolumab/Ipilimumab Falls Short of RFS End Point in Resected, Late-Stage Melanoma - 1 day
Mashup Score:2
The addition of ipilimumab to nivolumab as an adjuvant treatment failed to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1%...
-
The addition of ipilimumab to nivolumab as an adjuvant treatment failed to improve RFS in the ITT and PD-L1 of less than 1% populations compared with nivolumab alone in patients with resected stage IIIB to D/IV melanoma. @ProfGLongMIA #melcsm https://t.co/qJkJquQLyP - view on twitter
More coverage:
#melcsm
Mashup Score:2
OncLiveDr. Haigentz on the Importance of Adjuvant Osimertinib in EGFR+ NSCLC - 2 hours
Mashup Score:2
Missak Haigentz Jr., MD, discusses the importance of adjuvant osimertinib in EGFR-positive non–small cell lung...
-
.@DrHaigentz, MD, of @AtlanticHealth discusses the importance of adjuvant osimertinib in EGFR-positive non–small cell lung cancer. #lcsm https://t.co/crfWvq7myX - view on twitter
More coverage:
#lcsm
Mashup Score:2
OncLiveRisk Factors Associated With TA-TMA - 2 days
Mashup Score:2
Jeffrey Laurence, MD, reviews the risk factors for developing transplant-associated thrombotic microangiopathy, and the panel discusses how risk affects their decision to change or...
-
WATCH NOW: Samer Khaled, MD, @cityofhope; Christine Duncan, MD, @DanaFarber; Parameswaran Hari, MD, MRCP, MS, Medical @MCWCancerCenter; and Jeffrey Laurence, MD, @WeillCornell discuss risk factors associated with TA-TMA. #hemcsm https://t.co/Y3U78ArbAV https://t.co/Y3U78ArbAV - view on twitter
More coverage:
#hemcsm
Mashup Score:2
OncLiveLifileucel Yields Durable Responses in Pretreated Advanced Melanoma - 2 days
Mashup Score:2
The tumor-infiltrating lymphocyte therapy lifileucel was found to elicit durable responses in patients with advanced melanoma who were previously treated with an immune checkpoint...
-
The tumor-infiltrating lymphocyte therapy lifileucel was found to elicit durable responses in patients with advanced melanoma who were previously treated with an immune checkpoint inhibitor. @UofLBCC @AACR #AACR21 #mmsm https://t.co/ZCUmqYYdCX - view on twitter
John V. Heymach, MD, PhD, discusses the potential utility of afatinib in NRG1 fusion–positive non–small cell lung...
John V. Heymach, MD, PhD, of @MDAndersonNews, discusses the potential utility of afatinib in NRG1 fusion–positive non–small cell lung cancer. #lcsm https://t.co/gGLiBevto3 https://t.co/gGLiBevto3 - view on twitter